

## Understanding the True Eligibility Criteria for the Use of Monoclonal Antibody Treatments for COVID-19

Resource	Address
National Infusion Center Association (NICA). Resources for Healthcare Providers. Accessed February 24, 2022.	<a href="https://infusioncenter.org/healthcare-providers-mono-clonal-antibody-therapies">https://infusioncenter.org/healthcare-providers-mono-clonal-antibody-therapies</a>
RADx-UP Coordination and Data Collection Center (CDCC). Community Resources. Accessed February 24, 2022.	<a href="https://radx-up.org/learning-resources/">https://radx-up.org/learning-resources/</a>
National Institutes of Health (NIH) Community Engagement Alliance. Resources to Share. Accessed February 24, 2022.	<a href="https://covid19community.nih.gov/communication-resources">https://covid19community.nih.gov/communication-resources</a>
Centers for Disease Control and Prevention (CDC). Health Equity. Accessed February 24, 2022.	<a href="https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/index.html">https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/index.html</a>
National Institutes of Health (NIH). COVID-19 Vaccination Communication. December 2020. Accessed February 24, 2022.	<a href="https://obssr.od.nih.gov/wp-content/uploads/2020/12/COVIDReport_Final.pdf">https://obssr.od.nih.gov/wp-content/uploads/2020/12/COVIDReport_Final.pdf</a>
US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. Emergency Use Authorization (EUA) of REGEN-COV® (casirivimab and imdevimab). Revised January 2022.	<a href="https://www.fda.gov/media/145611/download">https://www.fda.gov/media/145611/download</a>
US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. Emergency Use Authorization (EUA) of Sotrovimab. Revised February 2022.	<a href="https://www.fda.gov/media/149534/download">https://www.fda.gov/media/149534/download</a>
US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab. Revised January 2022.	<a href="http://www.fda.gov/media/145802/download">www.fda.gov/media/145802/download</a>
US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. Emergency Use Authorization (EUA) of Bebtelovimab. Authorized February 2022.	<a href="https://www.fda.gov/media/156152/download">https://www.fda.gov/media/156152/download</a>
US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. Emergency Use Authorization (EUA) of EVUSHELD™ (tixagevimab co-packaged with cilgavimab). Authorized December 2021.	<a href="https://www.fda.gov/media/154701/download">https://www.fda.gov/media/154701/download</a>
Infectious Disease Society of America (IDSA). IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Last updated February 22, 2022.	<a href="https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/">https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/</a>
National Institutes of Health (NIH). COVID-19 Treatment Guidelines. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Last updated February 1, 2022.	<a href="https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf">https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf</a>
Centers for Disease Control and Prevention (CDC). SARS-CoV-2 Variant Classifications and Definitions. Last updated December 1, 2021.	<a href="http://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html">www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html</a>
Centers for Disease Control and Prevention (CDC). COVID Data Tracker. Last updated February 22, 2022.	<a href="http://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-proportions.html">www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-proportions.html</a>
Centers for Disease Control and Prevention (CDC). People with Certain Medical Conditions. Updated February 15, 2022.	<a href="https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html">https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html</a>
Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. <i>J Clin Invest</i> . 2020;130:5235-5244.	<a href="https://pubmed.ncbi.nlm.nih.gov/32634129/">https://pubmed.ncbi.nlm.nih.gov/32634129/</a>
Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. <i>Pharmacol Res Perspect</i> . 2019;7:e00535.	<a href="https://pubmed.ncbi.nlm.nih.gov/31859459/">https://pubmed.ncbi.nlm.nih.gov/31859459/</a>

Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. <i>Science</i> . 2020;369:1014-1018.	<a href="https://pubmed.ncbi.nlm.nih.gov/32540904/">https://pubmed.ncbi.nlm.nih.gov/32540904/</a>
Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> . 2021;593:130-135.	<a href="https://pubmed.ncbi.nlm.nih.gov/33684923/">https://pubmed.ncbi.nlm.nih.gov/33684923/</a>
Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. <i>Science</i> . 2020;369:1010-1014.	<a href="https://pubmed.ncbi.nlm.nih.gov/32540901/">https://pubmed.ncbi.nlm.nih.gov/32540901/</a>
Starr TN, Greaney AJ, Addetia A, et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. <i>Science</i> . 2021;371:850-854.	<a href="https://pubmed.ncbi.nlm.nih.gov/33495308/">https://pubmed.ncbi.nlm.nih.gov/33495308/</a>
Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. <i>N Engl J Med</i> . 2021;384:238-251.	<a href="https://pubmed.ncbi.nlm.nih.gov/33332778/">https://pubmed.ncbi.nlm.nih.gov/33332778/</a>
O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. <i>N Engl J Med</i> . 2021;385:1184-1195.	<a href="https://pubmed.ncbi.nlm.nih.gov/34347950/">https://pubmed.ncbi.nlm.nih.gov/34347950/</a>
O'Brien MP, Forleo-Neto E, Sarkar N, et al. Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: A randomized clinical trial. <i>JAMA</i> . 2022;327:432-441.	<a href="https://pubmed.ncbi.nlm.nih.gov/35029629/">https://pubmed.ncbi.nlm.nih.gov/35029629/</a>
RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. <i>Lancet</i> . 2022;399:665-676.	<a href="https://pubmed.ncbi.nlm.nih.gov/35151397/">https://pubmed.ncbi.nlm.nih.gov/35151397/</a>
Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. <i>JAMA</i> . 2021;325:632-644.	<a href="https://pubmed.ncbi.nlm.nih.gov/33475701/">https://pubmed.ncbi.nlm.nih.gov/33475701/</a>
Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. <i>N Engl J Med</i> . 2021;384:229-237.	<a href="https://pubmed.ncbi.nlm.nih.gov/33113295/">https://pubmed.ncbi.nlm.nih.gov/33113295/</a>
Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. <i>N Engl J Med</i> . 2021;385:1382-1392.	<a href="https://pubmed.ncbi.nlm.nih.gov/34260849/">https://pubmed.ncbi.nlm.nih.gov/34260849/</a>
Cohen MS, Nirula A, Mulligan MJ, et al. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities. <i>JAMA</i> . 2021;326:46-55.	<a href="https://pubmed.ncbi.nlm.nih.gov/34081073/">https://pubmed.ncbi.nlm.nih.gov/34081073/</a>
Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. <i>N Engl J Med</i> . 2021;385:1941-1950.	<a href="https://pubmed.ncbi.nlm.nih.gov/34706189/">https://pubmed.ncbi.nlm.nih.gov/34706189/</a>